Back to compounds

COMPOUND PROFILE / SMALL MOLECULES

GSBR-1290.

Research draft

GSBR-1290, also called aleniglipron, is an oral small-molecule GLP-1 receptor agonist.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

GSBR-1290, also called aleniglipron, is an oral small-molecule GLP-1 receptor agonist.

CLASSIFICATIONSmall molecules
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

It is designed to activate GLP-1 signalling without a peptide structure.

Human research

Registered human development studies exist. Registration alone does not establish efficacy or the most recent programme result.

Preclinical & other research

Preclinical work supports the target rationale.

Safety & unknowns

Trial-specific adverse effects and longer exposure require assessment before broad safety claims.

Regulatory status

Investigational; use the confirmed alias to follow updated trials.

Reported use & evidence

Research profile draft

The supplied GSBR-1290 profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds